Dow Jones
37.985,54 -400,55 (-1,04%) Nasdaq
15.809,73 -173,35 (-1,08%) Nikkei 225
38.405,66 +470,90 (+1,24%) EUR/USD
1,0684 -0,0041 (-0,38%) Bitcoin EUR
58.726,11 -631,68 (-1,06%) CMC Crypto 200
1.290,79 -48,27 (-3,61%)
Terumo Corp (TUO.DU)
| Chiusura precedente | 15,60 |
| Aperto | 15,90 |
| Denaro | 15,70 x 0 |
| Lettera | 16,20 x 0 |
| Min-Max giorno | 15,70 - 15,90 |
| Intervallo di 52 settimane | 11,70 - 18,50 |
| Volume | |
| Media Volume | 1 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireOrchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest
- GlobeNewswire
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat
